FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

Tesamorelin

Egrifta / TH9507

Growth Hormone Secretagogues

Tesamorelin (trade name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of the full 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability and receptor binding. It is the only FDA-approved GHRH analog, specifically indicated for the reduction of excess abdominal/visceral fat in HIV-infected patients with lipodystrophy. Its mechanism stimulates pulsatile endogenous GH release from the pituitary gland, preserving normal physiological feedback regulation unlike exogenous GH administration.

作用機序

Synthetic GHRH analog with a trans-3-hexenoic acid modification for enhanced stability. Specifically targets visceral adipose tissue reduction via GH-mediated lipolysis. FDA-approved mechanism preserves physiologic GH pulsatility and IGF-1 negative feedback.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

FDA-approved protocol: 2mg daily via subcutaneous injection. Research protocols follow the same dosing. Administered at a consistent time daily, typically in the morning.

研究ノート

Clinical Research Status

Tesamorelin received FDA approval in November 2010 for the treatment of HIV-associated lipodystrophy and is marketed by Theratechnologies as Egrifta and Egrifta SV (single-vial formulation). Multiple Phase III clinical trials (including the landmark studies with over 800 HIV patients) demonstrated statistically significant visceral adipose tissue reduction of approximately 15-18% over 26 weeks. Ongoing research explores applications in non-alcoholic fatty liver disease (NAFLD), cognitive decline in aging and HIV, and broader metabolic syndrome indications beyond the HIV population.

Key Published Findings

Pivotal trials demonstrated that tesamorelin 2mg daily subcutaneous injection reduced visceral adipose tissue by a mean of 15.2% versus placebo over 26 weeks, with continued maintenance of reduction over 52 weeks of treatment. A landmark study published in Neurology showed tesamorelin improved cognitive function in older adults with mild cognitive impairment or subjective cognitive complaints, suggesting neuroprotective properties mediated through GH/IGF-1 signaling. Research has also demonstrated improvements in liver fat content and NAFLD biomarkers, with hepatic fat reduction of approximately 35% in HIV patients with fatty liver.

Safety Profile

Tesamorelin is generally well-tolerated with the most common adverse effects being injection site reactions (erythema, pruritus, pain) reported in approximately 8-13% of clinical trial participants. Fluid retention, arthralgia, and paresthesias occur at rates slightly above placebo, consistent with physiological GH elevation. The compound is contraindicated in pregnancy, patients with active malignancy, and those with disruption of the hypothalamic-pituitary axis, and carries warnings regarding potential glucose intolerance.

Drug Interactions & Contraindications

Tesamorelin may reduce the efficacy of cortisol replacement therapy by increasing cortisol-binding globulin, and patients on glucocorticoid replacement should be monitored. It should be used cautiously with drugs affecting glucose metabolism (insulin, oral hypoglycemics) as GH elevation can impair insulin sensitivity. The compound is contraindicated in patients with active malignancy due to the proliferative effects of elevated GH/IGF-1, and patients with a history of hypothalamic-pituitary tumors should not use it.

Comparison to Related Compounds

Unlike synthetic GH (somatropin) which provides a constant supraphysiological GH level, tesamorelin preserves the natural pulsatile pattern of GH release and maintains hypothalamic-pituitary feedback, resulting in a more physiological GH profile. Compared to CJC-1295 (a modified GHRH analog popular in peptide research), tesamorelin has the advantage of FDA approval, extensive clinical trial data, and insurance coverage for qualifying HIV patients. Sermorelin is a shorter GHRH fragment (1-29) with similar mechanism but lower potency and shorter half-life, requiring more frequent dosing.

Community Observations

Practitioners and patients report that the visceral fat reduction becomes measurable on DEXA scans within 3-4 months, with peak effects at 6-9 months of consistent daily use. The research and TRT community has adopted tesamorelin for its GH-elevating effects beyond the HIV population, noting improvements in sleep quality, body composition, and skin quality. Users frequently note that results reverse within 3-6 months of discontinuation, indicating the need for ongoing treatment, and many physicians prescribe it alongside testosterone replacement therapy for synergistic metabolic benefits.

半減期

~26-38 minutes

再構成

Sterile water (provided with kit)

保存

乾燥粉末

Refrigerate 2-8C. Protect from light.

再溶解

Use immediately after reconstitution. Discard unused portion.

米国法的状況

FDA-approved (Rx only)

また知られる名前

EgriftaTH9507

よくある質問

Tesamorelinとは何ですか?

Tesamorelin (trade name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of the full 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability and receptor binding. It is the only FDA-approved GHRH analog, specifically indicated for the reduction of excess abdominal/visceral fat in HIV-infected patients with lipodystrophy. Its mechanism stimulates pulsatile endogenous GH release from the pituitary gland, preserving normal physiological feedback regulation unlike exogenous GH administration.

Tesamorelinはどのように作用しますか?

Synthetic GHRH analog with a trans-3-hexenoic acid modification for enhanced stability. Specifically targets visceral adipose tissue reduction via GH-mediated lipolysis. FDA-approved mechanism preserves physiologic GH pulsatility and IGF-1 negative feedback.

Tesamorelinの米国での規制状況は?

FDA-approved (Rx only)

Tesamorelinの半減期は?

~26-38 minutes

Tesamorelinの別名は?

Egrifta, TH9507

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む